Daily Stock Setups

Sunesis completes enrollment in Phase II leukemia trial

Posted on: Tue, 03 Nov 2009 05:09:00 EST

Symbols: SNSS

Are you looking to increase your ETF knowledge?

Nov 03, 2009 (Datamonitor via COMTEX) --
SNSS | Quote | Chart | News | PowerRating -- Sunesis Pharmaceuticals, a biopharmaceutical company, has completed enrollment in the Reveal-1 trial, a Phase II dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia or AML patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

The primary objective of the Reveal-1 trial is to evaluate voreloxin's anti-leukemic activity as a single agent, measured as either complete remission or complete remission without full platelet recovery.

The trial will also measure the duration of remission and survival. In order to qualify for the trial, patients had to be at least age 60 with previously untreated AML and satisfy at least one of the following poor prognosis factors: poor performance status (PS 2); intermediate or unfavorable cytogenetics; prior antecedent hematologic disorder; or an age greater than or equal to 70 years.

Patients enrolled in the trial were treated with voreloxin according to one of three dosing schedules: 72mg/m2 of voreloxin dosed weekly for three weeks, 72mg/m2 of voreloxin dosed weekly for two weeks, or 72 or 90mg/m2 of voreloxin dosed on days one and four.

Daniel Swisher, CEO of Sunesis, said: "The Reveal-1 trial's rapid accrual from initiation in May 2008 underscores a strong interest from investigators in voreloxin as a potential new treatment for AML. Previously reported interim data from this and other studies have demonstrated that voreloxin can induce durable complete remissions in a variety of AML patient populations, including highly underserved elderly patients.

"Results from Reveal-1 and our ongoing Phase Ib/II trial of voreloxin in combination with cytarabine in relapsed/refractory AML will contribute greatly to our clinical development strategy as we look to move in 2010 into a pivotal trial of voreloxin."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

For full details on Sunesis Pharmaceuticals Inc (SNSS) SNSS. Sunesis Pharmaceuticals Inc (SNSS) has Short Term PowerRatings at TradingMarkets. Details on Sunesis Pharmaceuticals Inc (SNSS) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.